For the Inventor, By the Inventor

Enter assignee name

Weesp, Netherlands

Duphar International Research Bv

Calculating rank

USPTO Granted Patents = 169

CIPO Patents = 2

Forward Citations = 3,526

Loading Chart...

Loading Chart...

186 inventors (with patents filed for the assignee):

Ineke Van Wijngaarden (27 out of 28 patents)

Cornelis G Kruse (16 out of 54 patents)

Derk Hamminga (15 out of 15 patents)

4. Sebastianus J Halkes (13 out of 14 patents)

5. Arnoldus C Grosscurt (12 out of 13 patents)

6. Wouter Wouters (11 out of 11 patents)

7. Roelof Van Hes (9 out of 13 patents)

8. Hans H Haeck (9 out of 9 patents)

9. Johannes Kuipers (9 out of 10 patents)

10. Hendrik Dolman (9 out of 10 patents)

11. Antonio Mourino (8 out of 8 patents)

12. Jan Van Dijk (8 out of 13 patents)

13. Marius S Brouwer (8 out of 9 patents)

14. Kobus Wellinga (7 out of 16 patents)

15. Jan Hartog (7 out of 11 patents)

Core Competencies:

Piperazine Compounds

Vitamin D Synthesis

Psychotropic Agents

Imidazolyl Compounds

Vaccine Formulations

Corticotropin Releasing Factor

Intranasal Vaccines

Benzisoxazole Derivatives

Cyanohydrin Derivatives

Dobutamine Compounds

Antimicrobial Activity

Lactulose Production

169 patents: Sort by Forward Citations

1. RE41425 - Piperazine and piperidine compounds (2010-07-05),

2. 6780864 - Piperazine and piperidine compounds (2004-08-24),

3. 6391896 - 3-Tetrahydropyridin-4-yl indoles for treatment of psychotic disorders (2002-05-21),

4. 6365743 - Process for the preparation of enantiomerically pure imidazolyl compounds (2002-04-02),

5. 6350750 - Quinoline and quinazoline derivatives having corticotropin releasing factor (CRF) antagonist activity (2002-02-26),

6. 6335326 - Benzisoxazole derivatives having d4-antagonistic activity (2002-01-01),

7. 6281216 - 2-aminoquinoline derivatives having d4-agonistic activity (2001-08-28),

8. 6225312 - Piperazine and piperidine compounds (2001-05-01),

9. 6214829 - Piperazine compounds, their preparation, and methods of using them (2001-04-10),

10. 6183780 - Oral delayed immediate release formulation and method for preparing the same (2001-02-06),

11. 6090812 - Piperazine and piperidine compounds (2000-07-18),

12. 6080878 - Method of preparing 16-dehydro vitamin D compounds (2000-06-27),

13. 6075015 - Vitamin D compounds and method of preparing these compounds (2000-06-13),

14. 6072062 - Synthesis of C.sub.18 -modified vitamin D compounds and compounds (2000-06-06),

15. 5948909 - Process for the stereoselective preparation of a hetero-bicyclic alcohol (1999-09-07),

Company Overview

Duphar International Research Bv, located in Weesp, Netherlands, specializes in the development and manufacturing of pharmaceutical compounds. The company focuses on innovative areas such as piperazine compounds, vitamin D synthesis, and psychotropic agents, contributing to advancements in mental health and wellness. Additionally, Duphar is engaged in research related to vaccine formulations, intranasal vaccines, and various derivatives, positioning itself at the forefront of pharmaceutical innovation and therapeutic solutions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

169 Patents

#1 in Weesp

#54 in Netherlands

#4,896 in the World

Weesp, Netherlands

Duphar International Research Bv

Forward Citations = 3,526

186 inventors:

Ineke Van Wijngaarden (27 out of 28 patents)

Cornelis G Kruse (16 out of 54 patents)

Derk Hamminga (15 out of 15 patents)

4. Sebastianus J Halkes (13 out of 14 patents)

5. Arnoldus C Grosscurt (12 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Duphar International Research Bv. Retrieved from https://idiyas.com/company/duphar-international-research-bv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…